{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-028646","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2025-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.690674+00:00","generated_at":"2026-05-23T22:43:30.390481+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Executive Chairman Sapirstein resigns; Interim CFO Fedasz appointed Interim CEO","bullets":["James Sapirstein resigned as Executive Chairman and Board member, effective March 28, 2025.","Karina Fedasz, 52, previously Interim CFO, appointed Interim CEO effective April 2, 2025.","Fedasz has background in finance, M&A, and capital raising; formerly CFO at IDW Media Holdings and Head of Business Development at Evofem Biosciences."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-028646","json":"https://secwatch.observer/filing/0001213900-25-028646.json","markdown":"https://secwatch.observer/filing/0001213900-25-028646.md","text":"https://secwatch.observer/filing/0001213900-25-028646.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025028646/0001213900-25-028646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025028646/ea0237140-8k_oncon.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T22:43:30.390481+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3487da2128","claim":"Karina Fedasz was appointed as Interim Chief Executive Officer at Onconetix, Inc..","evidence_excerpt":"On April 2, 2025, the Company appointed Karina Fedasz, 52, the Company’s Interim Chief Financial Officer, as Interim Chief Executive Officer of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025028646/0001213900-25-028646-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"b81dbaf96e","claim":"James Sapirstein resigned as Executive Chairman at Onconetix, Inc..","evidence_excerpt":"Effective as of March 28, 2025, James Sapirstein resigned as Executive Chairman and a member of the Board of Directors (the “Board”) of Onconetix, Inc. (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390025028646/0001213900-25-028646-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}